Recombinant Vaccines represent an innovative approach to vaccine development that utilizes genetic engineering techniques to produce vaccines with enhanced safety, efficacy, and specificity. These vaccines are created by inserting genes encoding specific antigens or proteins from a pathogen into a harmless vector, such as a virus or bacterium, which then delivers the antigen to the immune system, stimulating a protective immune response.
One of the key advantages of recombinant vaccines is their ability to produce highly purified antigens that are specific to the target pathogen. By isolating and purifying the antigenic proteins responsible for inducing immunity, recombinant vaccines minimize the risk of unwanted side effects associated with whole-pathogen vaccines. Recombinant vaccines can be designed to target a wide range of pathogens, including viruses, bacteria, and parasites, making them versatile tools for preventing infectious diseases. Examples of recombinant vaccines include those against hepatitis B, human papillomavirus (HPV), and COVID-19. In addition to their specificity, recombinant vaccines offer other advantages over traditional vaccine production methods. They can be produced using well-established manufacturing processes, allowing for rapid scale-up and production of large quantities of vaccine doses. This scalability is particularly important during pandemics or outbreaks when there is an urgent need for vaccines. Furthermore, recombinant vaccines are often safer than traditional vaccines because they do not contain live or inactivated forms of the pathogen. This reduces the risk of vaccine-associated adverse events and allows for their use in immunocompromised individuals or those with underlying health conditions.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia